neffy in Canada: Same Epinephrine. New Delivery Option. | Ayel L. R. Batac
neffy in Canada: Same Epinephrine. New Delivery Option.
May 15, 2026
- neffy® is a 2 mg epinephrine nasal spray authorized in Canada for emergency treatment of allergic reactions in people who weigh 30 kg or more.
- Epinephrine remains the first-line emergency treatment for anaphylaxis.
- neffy does not prevent allergic reactions; after epinephrine is used, people should call 911 or contact local emergency services.
- Drug-level and body-response studies support neffy as an emergency epinephrine delivery option, but real-world use during actual anaphylaxis events still needs to be studied.
- A new delivery option only helps if people know when to use it, how to use it, and what to do afterward.
What changes when the medication is the same, but the delivery option changes?
That is the question I keep coming back to as neffy becomes available in Canada. neffy is still epinephrine. It is still intended for emergency treatment of severe allergic reactions, including anaphylaxis. But instead of being injected into the thigh, it is sprayed into one nostril.
Health Canada has authorized neffy for emergency treatment of allergic reactions, including anaphylaxis, in adults and children who weigh 30 kg or more. These reactions may be triggered by insect stings or bites, foods, medications, or other allergens, or may be idiopathic or exercise-induced. Health Canada has not authorized neffy for patients under 30 kg.
This is not only a product story. It’s a preparedness story.
What neffy Is, and What It Is Not
neffy is a needle-free epinephrine nasal spray for emergencies. It is not an allergy cure. It does not prevent allergic reactions. It does not replace allergen avoidance, an anaphylaxis emergency plan, or contacting emergency services after epinephrine is used.
According to the Canadian product monograph, the recommended dose is one spray, containing 2 mg of epinephrine, into one nostril. If symptoms do not improve or worsen after the first dose, a second dose may be given in the same nostril using a new nasal spray starting five minutes after the first dose. The product monograph also recommends that patients have immediate access to two neffy nasal sprays at all times.
The device may look simple, but the situation is not simple. Anaphylaxis can progress quickly. A nasal spray may feel familiar, but neffy is still epinephrine for a potentially life-threatening emergency.
For some people, neffy may become an alternative to an auto-injector. For others, the right choice may depend on clinical history, preferences, availability, and the emergency plan.
The Device Is Part of the Intervention
In health systems research, it’s easy to describe a medication by its active ingredient. In real life, the delivery device also shapes behaviour.
A person may know that epinephrine is recommended and still hesitate. They may be afraid of needles. A parent or caregiver may worry about using an injectable device incorrectly or causing harm because they are unsure of the steps. They may be uncertain whether symptoms are severe enough. They may not remember what to do under stress.
That’s why neffy matters beyond pharmacology. A needle-free delivery device may feel less intimidating for some patients, caregivers, teachers, or bystanders. It may also be easier to explain in some community settings.
But a different device also creates a different training need. The practical question is not only, “does this person carry epinephrine?”. The better question is, “which epinephrine device does this person carry, where is it kept, who knows how to use it, and who calls emergency services afterward?”.
That is device-specific preparedness.
What the Evidence Can and Cannot Say
The key evidence question is not whether epinephrine works. Epinephrine is already the first-line emergency treatment for anaphylaxis.
The key question is whether a nasal spray can deliver epinephrine into the body in a way that supports emergency use. Health Canada’s product monograph states that controlled clinical trials for treatment of anaphylaxis have not been performed with epinephrine, and that after one nasal dose of neffy 2 mg, the epinephrine concentration profile was overall within the range seen after intramuscular epinephrine injection over 60 minutes.
Published neffy research provides supportive pharmacologic evidence. In a repeat-dosing study, neffy produced epinephrine levels and physiologic responses within a comparable range to intramuscular epinephrine, including during induced allergic rhinitis with nasal symptoms. The same study supported same-nostril repeat dosing.
These are drug-level and body-response studies. They help answer whether epinephrine reaches the body. They do not prove that neffy will improve outcomes in real-world emergencies compared with existing epinephrine devices, or that every person will carry it consistently and use it correctly.
Broader intranasal adrenaline research also supports the scientific plausibility of nasal delivery, but not all of that research is neffy-specific. A recent review concluded that clinical efficacy data remain limited and that long-term real-world effectiveness and adherence data in community settings are not yet available.
The careful summary is this: current evidence supports neffy as an emergency epinephrine delivery option, but confidence in the device still needs to be matched with training, clear instructions, and real-world follow-up.
What Canadians Should Do Next
Before neffy becomes part of someone’s emergency plan, three details need to be clear.
First, check eligibility. neffy 2 mg is authorized in Canada for people who weigh 30 kg or more. The 1 mg dose for children under 30 kg is not available in Canada at this time.
Second, ask about cost and availability. Food Allergy Canada reports that neffy is expected to be available in Canadian pharmacies starting in summer 2026, and that price will depend on coverage and reimbursement arrangements with provinces and insurance companies.
Third, update the emergency plan by device. If a person carries neffy, the plan should state that it is a single-use nasal spray, that a second dose may be given in the same nostril with a new device after five minutes if symptoms do not improve or worsen, and that 911 or local emergency services should be called after epinephrine is used. The device should be named in the emergency plan, not just the medication.
For patients and families, the next step is not to decide alone. Ask your allergist, family physician, nurse practitioner, or pharmacist whether neffy is appropriate for your weight, allergy history, daily settings, preferences, and emergency plan.
As neffy becomes available in Canada, its importance will not be only that it offers another epinephrine option. Its importance will be whether people know how to use that option before an emergency happens.
Confidence is not something families should have to find in the middle of an emergency; it should be built before the emergency happens. A new epinephrine delivery option only helps if the person carrying it, and the people around them, know exactly when and how to use it.
Preparedness starts before the emergency.
-Ayel
Disclaimer: Mention of specific medications, drugs, devices, prevention strategies, or therapeutic agents in this blog is for informational and educational purposes only and does not constitute endorsement, recommendation, or promotion by the author. Clinical decisions should be made in consultation with qualified healthcare professionals and based on current evidence and applicable regulatory guidance.
The author declares no financial relationships with manufacturers of any drugs, medications, or devices mentioned in this post.
\(~\)
\(~\)
